Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity

Intrathecal and/or high-dose intravenous administration of methotrexate (MTX) in the treatment of malignancies such as acute lymphoblastic leukaemia (ALL) has been associated with cases of mild to severe neurotoxicity. The pathogenic mechanism of neurotoxicity is not clear, possibly MTX-associated b...

Full description

Bibliographic Details
Main Authors: Vezmar Sandra, Bode Udo, Jaehde Ulrich
Format: Article
Language:English
Published: Society of Medical Biochemists of Serbia, Belgrade 2009-01-01
Series:Journal of Medical Biochemistry
Subjects:
csf
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2009/1452-82580901011V.pdf
id doaj-b2f8ec3f078c406d9715d893ba0a4d45
record_format Article
spelling doaj-b2f8ec3f078c406d9715d893ba0a4d452020-11-25T02:09:59ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662009-01-0128111151452-82580901011VMethotrexate-associated biochemical alterations in a patient with chronic neurotoxicityVezmar Sandra0Bode Udo1Jaehde Ulrich2Institute of Pharmacy, University of Bonn, Germany + Faculty of Pharmacy, University of Belgrade, SerbiaChildren's Hospital, Department of Paediatric Haematology and Oncology, University of Bonn, GermanyInstitute of Pharmacy, Department of Clinical Pharmacy, University of Bonn, GermanyIntrathecal and/or high-dose intravenous administration of methotrexate (MTX) in the treatment of malignancies such as acute lymphoblastic leukaemia (ALL) has been associated with cases of mild to severe neurotoxicity. The pathogenic mechanism of neurotoxicity is not clear, possibly MTX-associated biochemical alterations of the folate and methyl-transfer metabolic pathways play an important role. We report a case of an adult patient treated for ALL relapse with signs of chronic leukoencephalopathy associated with MTX administration. In order to assess alterations in the folate and methyl-transfer pathway we determined 5-methyltetrahydrofolate (5-methyl-THF), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in the cerebrospinal fluid (CSF) of the patient. Three CSF samples were obtained by lumbar punction within a four-month period. Concentrations of the metabolites were measured using validated bioanalytical methods based on HPLC with UV and fluorescence detection. The results showed two-fold lower 5-methyl-THF levels (29.3-31.8 nmol/L) in all obtained samples compared to reference values. SAM concentrations were even more than five-fold lower in two samples (5-34.2 nmol/L). SAH concentrations were in the range 7.5-14.3 nmol/L. Our patient had pronounced alterations in the folate and methyltransfer pathway which indicate that MTX-associated biochemical alterations of these pathways may play an important role in the development of leukoencephalopathy.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2009/1452-82580901011V.pdfmethotrexatecsf5-methyltetrahydrofolates-adenosylmethionineneurotoxicity
collection DOAJ
language English
format Article
sources DOAJ
author Vezmar Sandra
Bode Udo
Jaehde Ulrich
spellingShingle Vezmar Sandra
Bode Udo
Jaehde Ulrich
Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
Journal of Medical Biochemistry
methotrexate
csf
5-methyltetrahydrofolate
s-adenosylmethionine
neurotoxicity
author_facet Vezmar Sandra
Bode Udo
Jaehde Ulrich
author_sort Vezmar Sandra
title Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
title_short Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
title_full Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
title_fullStr Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
title_full_unstemmed Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
title_sort methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity
publisher Society of Medical Biochemists of Serbia, Belgrade
series Journal of Medical Biochemistry
issn 1452-8258
1452-8266
publishDate 2009-01-01
description Intrathecal and/or high-dose intravenous administration of methotrexate (MTX) in the treatment of malignancies such as acute lymphoblastic leukaemia (ALL) has been associated with cases of mild to severe neurotoxicity. The pathogenic mechanism of neurotoxicity is not clear, possibly MTX-associated biochemical alterations of the folate and methyl-transfer metabolic pathways play an important role. We report a case of an adult patient treated for ALL relapse with signs of chronic leukoencephalopathy associated with MTX administration. In order to assess alterations in the folate and methyl-transfer pathway we determined 5-methyltetrahydrofolate (5-methyl-THF), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in the cerebrospinal fluid (CSF) of the patient. Three CSF samples were obtained by lumbar punction within a four-month period. Concentrations of the metabolites were measured using validated bioanalytical methods based on HPLC with UV and fluorescence detection. The results showed two-fold lower 5-methyl-THF levels (29.3-31.8 nmol/L) in all obtained samples compared to reference values. SAM concentrations were even more than five-fold lower in two samples (5-34.2 nmol/L). SAH concentrations were in the range 7.5-14.3 nmol/L. Our patient had pronounced alterations in the folate and methyltransfer pathway which indicate that MTX-associated biochemical alterations of these pathways may play an important role in the development of leukoencephalopathy.
topic methotrexate
csf
5-methyltetrahydrofolate
s-adenosylmethionine
neurotoxicity
url https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2009/1452-82580901011V.pdf
work_keys_str_mv AT vezmarsandra methotrexateassociatedbiochemicalalterationsinapatientwithchronicneurotoxicity
AT bodeudo methotrexateassociatedbiochemicalalterationsinapatientwithchronicneurotoxicity
AT jaehdeulrich methotrexateassociatedbiochemicalalterationsinapatientwithchronicneurotoxicity
_version_ 1724921338048544768